Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies

J Wenzel - Nature Reviews Rheumatology, 2019 - nature.com
Cutaneous lupus erythematosus (CLE) is an autoimmune disease that can present as an
isolated skin disease or as a manifestation within the spectrum of systemic lupus …

Antigen presentation, autoantibody production, and therapeutic targets in autoimmune liver disease

AK Horst, KG Kumashie, K Neumann, L Diehl… - Cellular & molecular …, 2021 - nature.com
The liver is an important immunological organ that controls systemic tolerance. The liver
harbors professional and unconventional antigen-presenting cells that are crucial for …

Long-term exposure to fine particulate matter and ozone and the onset of systemic autoimmune rheumatic diseases: an open cohort study in Quebec, Canada

N Zhao, A Smargiassi, S Jean, P Gamache… - Arthritis Research & …, 2022 - Springer
Objectives To estimate associations between fine particulate matter (PM2. 5) and ozone and
the onset of systemic autoimmune rheumatic diseases (SARDs). Methods An open cohort of …

Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis

MMV de Figueiredo Caldas, KPM de Azevedo… - Advances in …, 2021 - Springer
Abstract Background Systemic sclerosis (SSc) is a clinically complex and challenging
disease, that leads to skin fibrosis. Its most frequent complication is interstitial lung disease …

The impact of Rituximab administered before transplantation in patients undergoing allogeneic hematopoietic stem cell transplantation: a real-world study

X Wei, Y Xie, R Jiang, H Li, H Wu, Y Zhang… - Frontiers in …, 2022 - frontiersin.org
Rituximab is used to eliminate B cells as a chimeric monoclonal antibody directed against
CD20, a B-cell antigen expressed on B cells. To explore the impact of rituximab …

Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases

M Su, C Zhao, S Luo - Autoimmunity Reviews, 2022 - Elsevier
Chimeric antigen receptor (CAR) based therapies have been adopted as an option for
treating autoimmune diseases from the field of blood malignancies by targeting immune …

Immunosuppressive treatment in antiphospholipid syndrome: is it worth it?

I Mormile, F Granata, A Punziano, A de Paulis… - Biomedicines, 2021 - mdpi.com
The antiphospholipid syndrome (APS) is characterized by the development of venous and/or
arterial thrombosis and pregnancy morbidity in patients with persistent antiphospholipid …

Emerging therapeutics in the management of connective tissue disease. Part I. Lupus erythematosus and Sjögren syndrome

L Skudalski, N Shahriari, K Torre, S Santiago… - Journal of the American …, 2022 - Elsevier
The management of connective tissue diseases is dramatically evolving with the advent of
biologics and novel oral systemic therapeutics. Despite involvement in the care of these …

Autoimmune pre-disease

JE Hundt, MH Hoffmann, KT Amber… - Frontiers in …, 2023 - frontiersin.org
According to the revised Witebsky postulates, diseases are of an autoimmune nature if,(i) the
clinical phenotype can be reproduced through the transfer of autoantibodies and/or …

Methotrexate induced neurotoxicity in a patient with rheumatoid arthritis on rituximab therapy: a case-based review

N Kougkas, A Dara, E Pagkopoulou… - Rheumatology …, 2022 - Springer
Rheumatoid arthritis (RA) is a systemic inflammatory disease treated with conventional and
biologic disease-modifying drugs. Methotrexate is the anchor drug for the treatment of RA …